BPC-157
Synthetic 15-Amino-Acid Research Peptide
- Form
- Lyophilized powder
- Storage
- -20°C (lyophilized)
- Origin
- USA lab
from$69
BPC-157 is a synthetic peptide reference material used in preclinical and in-vitro investigations involving cellular signaling, endothelial response, and experimental tissue models.
- Cellular migration and signaling research
- Endothelial-response models
- In-vitro peptide-interaction studies
SKU: AP-BPC157-5MG
3 vial minimum per order — mix any products
Research Use Only
All products are intended solely for laboratory research and are not for human or animal consumption. By purchasing, the buyer agrees to use these products in compliance with all applicable laws.
Reconstitution ReferenceOptional — how strong is the mixed vial?
Mixing a powder vial with water? Fill in the fields — results update as you type.
Mixing 5 mg of peptide into 2 mL of water makes a 2.5 mg/mL solution. Each 0.1 mL contains 0.25 mg.
Reference for in-vitro laboratory handling only. Outputs describe the physical properties of the reconstituted vial (concentration and mass drawn) — they are not dosing guidance, administration instructions, or medical advice. Verify all measurements independently.
The science behind BPC-157
A structured overview of the published preclinical and in-vitro literature surrounding BPC-157 as a research compound.
BPC-157 (Body Protection Compound-157) is a synthetic, stable pentadecapeptide — a chain of fifteen amino acids. Its sequence corresponds to a partial fragment of a larger body protection compound originally isolated from human gastric juice, and it is notable in the research setting for remaining stable in aqueous solution and in gastric environments used in laboratory models.
Within the peptide-research community, BPC-157 is one of the most frequently referenced compounds in the tissue-repair and regenerative literature. It is studied almost exclusively in preclinical, animal, and in-vitro systems, where investigators use it as a reference tool to probe cellular signaling, angiogenesis, and experimental models of connective-tissue response.
The material supplied here is intended solely as a laboratory reference standard. It is not a drug, is not approved by the FDA or any health authority for human or veterinary use, and the summaries below describe only what has been reported in published research — not outcomes, benefits, or applications of any kind.
BPC-157 was derived from research into the protective peptides present in gastric juice. Investigators identified a partial sequence of the native body protection compound and synthesized the stable fifteen-amino-acid fragment now studied as BPC-157. Its resistance to hydrolysis and degradation made it attractive as a stable experimental compound relative to many naturally occurring peptides.
Much of the foundational work originates from a body of preclinical research led by Sikirić and colleagues, later expanded by independent groups examining musculoskeletal and vascular models. The literature is predominantly composed of rodent and in-vitro studies; controlled human clinical trials establishing efficacy for any use have not been completed.
The mechanisms attributed to BPC-157 in the literature remain under active investigation and are not fully established. The most frequently discussed pathway involves interaction with the nitric-oxide (NO) system, where researchers have reported modulation of NO-related signaling in experimental models.
A second recurring theme is angiogenesis — the formation of new blood vessels. Preclinical reports describe upregulation of vascular growth-factor signaling (including the VEGFR2 pathway) in cellular and animal models, which researchers connect to observed changes in experimental tissue-repair systems.
Additional in-vitro work has examined effects on fibroblast survival, migration, and growth-factor receptor expression. These findings are mechanistic and exploratory; they describe observations within controlled laboratory systems and should not be read as demonstrated effects in humans.
Tendon & ligament models
Cited extensively in studies of tendon-fibroblast outgrowth, cell survival, and migration, as well as experimental tendon-to-bone and ligament healing systems.
Angiogenesis research
Used as a probe in vascular models examining new-vessel formation and VEGFR2-associated growth-factor signaling.
Gastrointestinal models
Studied in preclinical models of gastric and intestinal mucosal integrity, reflecting the peptide’s origin in gastric-juice research.
Musculoskeletal soft tissue
Referenced in reviews of muscle, tendon, and connective-tissue response within controlled animal systems.
Nitric-oxide signaling
Examined for reported interactions with the NO system and related vascular-tone pathways in experimental settings.
Neurological models
Explored in early preclinical neuroprotection and gut–brain-axis research, an emerging and still-limited area of the literature.
What is BPC-157?
A synthetic fifteen-amino-acid research peptide corresponding to a partial fragment of a body protection compound identified in gastric juice. It is supplied strictly as a laboratory reference material.
Is BPC-157 approved for human or veterinary use?
No. BPC-157 is not approved by the FDA or any regulatory authority for human or animal use. It is sold exclusively for in-vitro and laboratory research and is not for consumption.
What kind of research references BPC-157?
The published literature is overwhelmingly preclinical — rodent models and in-vitro cellular studies examining tissue-repair signaling, angiogenesis, and gastrointestinal models. Controlled human efficacy trials have not been completed.
How is the reference material characterized?
Each released lot is supplied as a lyophilized powder with a lot-specific certificate of analysis reporting HPLC purity of ≥ 99%. The certificate is tied to the specific released lot.
How should the compound be stored?
Lyophilized BPC-157 is typically stored at -20°C, protected from light and moisture. Handling should follow standard laboratory practice for peptide reference materials. We do not provide reconstitution, dosing, or administration guidance.
- Chang C-H, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing. J Appl Physiol (2011).
- Chang C-H, et al. Pentadecapeptide BPC 157 enhances growth-hormone receptor expression in tendon fibroblasts. Molecules (2014).
- Seiwerth S, et al. BPC 157 and blood vessels. Curr Pharm Des (2018).
- Gwyer D, et al. Gastric pentadecapeptide BPC 157 and its role in accelerating musculoskeletal soft-tissue healing. Cell Tissue Res (2019).
- Sikirić P, et al. Stable gastric pentadecapeptide BPC 157 — review of the preclinical literature.
Links open a curated peer-reviewed search on PubMed. Allpointe Bio Research is not affiliated with the cited authors or publishers.
Research-Use Statement
The information above is provided for educational and scientific-reference purposes only and summarizes findings reported in the published preclinical and in-vitro literature. It is not medical advice and does not describe outcomes, benefits, or applications for humans or animals. BPC-157 is supplied strictly as a laboratory reference material for in-vitro and research use only — it is not a drug or supplement, is not approved for human or veterinary use, and is not for consumption. Allpointe Bio Research does not provide clinical, dosing, reconstitution, or administration guidance.